This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Mitchell Ho, PhD
Senior Investigator, Laboratory of Molecular Biology at NIH NCI


Mitchell Ho is a Senior Investigator at the NIH. He is Chief of the Antibody Therapy Section for NCI’s Laboratory of Molecular Biology and Director of the NCI Antibody Engineering Program. His research focuses on the role of cell surface glypicans in cancer signaling and develops antibody engineering technologies to create novel therapies. His contributions to antibody engineering field include (1) research on the role of glypicans as a new family of cancer antigens and generation of antibody-based therapies including immunotoxins and CAR T cells to GPC2 and GPC3 for treating liver cancer and other solid tumors; (2) discovery of nanobodies that are capable of reaching buried functional domains in the receptor/ligand complexes to inhibit cancer signaling; (3) development of antibody engineering methods including mammalian cell display, humanization of rabbit antibodies, construction of large phage displayed shark and camel nanobody libraries.

He received a B.S. from East China Normal University and a M.A. from San Francisco State University. After working at DNAX Research Institute and Protein Design Labs as a research associate, he moved to the University of Illinois at Urbana-Champaign where he received a Ph.D. as a NIH/NIDA National Research Service Award pre-doctoral fellow. He completed a postdoctoral fellowship with Ira Pastan at the NCI.

He has received many honors including the APAO Scientific Achievement Award, NIH DDIR Innovation Award, and NCI Director’s Intramural Innovation Award. He is the Co-Chair of the Department of Biochemistry, Chemistry, Pharmacology and Toxicology for the FAES Graduate School at the NIH. He also serves as the Editor-in-Chief of Antibody Therapeutics.

Agenda Sessions

  • Co-Chairs’ Remarks